+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1998 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effectiveness and duration of pain relief provided by a single infusion of 2R,6R-hydroxynorketamine compared with ketamine and saline in adults with chronic neuropathic pain of the extremities lasting longer than three months. The study is a randomized, double-blind, three-way crossover trial designed to compare these treatments on pain intensity, pain qualities, physical function, pain interference, sleep disturbance, and quality of life. Participants will receive each of the three study drugs2R,6R-hydroxynorketamine, ketamine, and salinein a random order, with each infusion given over 45 minutes and spaced five weeks apart, totaling a 15-week treatment period. The study uses a crossover design where participants experience all treatments in different sequences. Safety and efficacy are monitored throughout, with baseline and follow-up assessments including blood tests, ECGs, and physical exams. During the study, participants will undergo quantitative sensory and pain evaluations before the first treatment and on days 7, 14, 21, and 35 after each infusion. They will also complete patient-reported pain outcome questionnaires to assess changes in pain and related symptoms. Researchers will monitor safety, lab results, vital signs, and liver function throughout the trial. Participants are advised to continue their regular pain medications and use additional analgesics only as needed. The total study duration per participant is approximately 15 weeks of treatment plus assessment periods.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
1 location
E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.

Age: 18Years +All GendersPhase 2
20 locations
W

Actively Recruiting

Researchers are evaluating the use of XYOSTED as a testosterone replacement therapy in adolescent males aged 12 to under 18 years with primary or secondary hypogonadism, a condition where the body produces little or no testosterone. This Phase 34 open-label study aims to assess how well XYOSTED supports the continuation or start of puberty, along with its safety and the testosterone levels it maintains. Participants will receive XYOSTED injections at doses tailored to their weight and targeted pubertal stage. Dose adjustments will be made based on testosterone levels measured at specific intervals after dosing, with evaluations approximately every three months to reach the desired hormone levels. After completing the 52-week initial study period, participants may enter a 24-month extension to further monitor long-term safety and treatment effects. Throughout the study and extension, participants will undergo clinical examinations including pubertal staging, blood tests for testosterone and other labs, bone density scans, body composition assessments, and X-rays to monitor bone age. Researchers will track changes in puberty progression, bone health, body measurements, and hormone levels. Participants will attend regular clinic visits every six months during the extension phase to continue safety and pharmacokinetic evaluations.

Age: 12Years - 17YearsMALEPhase 3
20 locations
L

Actively Recruiting

This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.

Age: 18Years - 65YearsAll GendersPhase 3
23 locations
C

Actively Recruiting

This research aims to evaluate the biomechanical effects of the Ossur Power Knee, a unique microprocessor-controlled prosthetic knee that actively powers knee flexion and extension using a motor. The study compares this powered knee to the Ossur Rheo XC, a passive microprocessor-controlled knee that adjusts resistance without active power. Researchers will also examine differences in prosthetic use between male and female transfemoral amputees to identify any gender-specific mobility variations. Participants will be fitted with each prosthetic knee in a randomized crossover design, wearing each device for a one-month accommodation period before evaluation. The Ossur Power Knee offers powered movement during walking and other activities, while the Ossur Rheo XC modulates damping passively. The study involves about 20 unilateral transfemoral amputees who will undergo biomechanical testing in a motion analysis laboratory to assess gait and functional activities using both devices. Throughout the study, participants will complete questionnaires and keep diaries to report comfort, exertion, and stability with each knee. Biomechanical data such as walking speed, metabolic energy cost, step length, and pelvic motion will be measured after each accommodation period. The research will help improve understanding of these prosthetic knees impact on mobility, potentially guiding prosthetic selection and design improvements. The study is expected to continue until early 2027.

Age: 45Years - 75YearsAll GendersPhase Not Applicable
1 location
B

Actively Recruiting

Researchers are investigating whether touch sensation can be restored to the breast after mastectomy using neural stimulation. This trial aims to gather information to guide future studies on the safety, effectiveness, and acceptability of this approach. The study focuses on women undergoing bilateral mastectomy with two-stage reconstruction for certain types of breast cancer or breast cancer risk reduction. Participants will receive a small medical device called the Bionic Breast implant, temporarily placed in one breast during the mastectomy. This device sends tiny electrical currents to nerves to create sensory stimulation in response to touch or pressure. The device will later be removed, and the study will assess the sensations produced by the stimulation. During the study, participants will complete psychophysical tasks seven months after mastectomy, implantation, and device removal to evaluate sensation and stimulation levels. Researchers will measure outcomes such as stimulation intensity, ability to distinguish different stimuli, and mapping of sensation areas. Participants will be monitored throughout for safety and adherence, with the total study duration spanning several months post-surgery.

Age: 18Years +FEMALEPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.

Age: 18Years +All GendersPhase 2
36 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating diabetic peripheral neuropathic pain DPNP. This study is part of a larger chronic pain master protocol aimed at speeding up the development of new treatments for chronic pain conditions. Participants have diabetes and suffer from symmetrical nerve pain in their lower limbs. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment. The treatment phase will last 8 weeks, during which pain and related symptoms will be monitored and compared between the groups. During the study, participants will have their pain intensity measured using a numeric rating scale at the start and at week 8. Other assessments include pain interference, overall improvement, sleep quality, emotional functioning, and daily use of rescue medication. The study involves regular monitoring to evaluate these outcomes and ensure participant safety throughout the 8-week treatment period.

Age: 18Years +All GendersPhase 2
36 locations

1-10 of 1,998

1